BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DEMENTIA RESEARCHER - ECPv6.14.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DEMENTIA RESEARCHER
X-ORIGINAL-URL:https://www.dementiaresearcher.nihr.ac.uk
X-WR-CALDESC:Events for DEMENTIA RESEARCHER
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260112
DTEND;VALUE=DATE:20260115
DTSTAMP:20260622T185510
CREATED:20251203T225307Z
LAST-MODIFIED:20251203T225307Z
UID:10002011-1768176000-1768435199@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Human Amyloid Imaging Conference
DESCRIPTION:The overall goal of the Human Amyloid Imaging conference is to support active communication and collaboration between academic and industry scientists doing cutting-edge research in human imaging of amyloid-beta\, tau\, and/or other biomarkers that pertain to Alzheimer’s disease and related disorders. \nHAI 2026 will be held once again in beautiful San Juan\, Puerto Rico\, at the Puerto Rico Convention Center\, from Monday\, January 12 through Wednesday\, January 14. \nThe meeting will also provide related perspectives from neuropathology\, neurochemistry\, psychology\, neurology\, molecular imaging\, clinical trials\, and biomarker research. \n\nAttendees will have the opportunity to review the basic\, fundamental principles of PET imaging of amyloid and tau radiotracers. This includes radiotracer synthesis\, PET acquisition and data processing (e.g.\, application of corrections for the partial volume effect\, co-registration with structural data). Aspects of radiotracer discovery and optimization and first in human applications are other important topics.\nData analysis procedures discussed will include voxel-based and region-based imaging approaches\, masking for vulnerable regions\, evaluation of reference regions or standards\, choice of statistical procedures and specific use of control groups from older age groups. Important topics include data harmonization methods for imaging and biofluid biomarkers.\nNeuropathology concepts will be discussed in the context of applications that include further characterization of neurodegeneration in AD and related disorders\, disease subtypes\, disease staging\, and risk factors. Additional investigations of importance include neuropathological evaluation of PET radiotracer properties (e.g.\, distribution\, localization of specific and off-target binding) and correspondence between antemortem PET and postmortem measures.\nBiofluid biomarker development\, validation\, and application in AD and related disorders will be discussed. This will include efforts to understand relationships across established and emergent biofluid biomarkers and comparison of these outcomes to amyloid and tau PET measures.\nThe concept of biomarker positivity will continue to be extensively discussed\, and the attendees should be able to characterize the advantages and disadvantages of both dichotomized and continuous variable approaches to imaging and non-imaging biomarkers relevant to the human amyloid imaging field and with respect to specific purposes or intended uses of the outcome.\nAttendees will have the opportunity to evaluate amyloid and tau data in specific clinical and clinical research contexts\, including review of typical findings in AD dementia\, mild cognitive impairment due to AD\, and in clinically normal individuals. This includes further elucidation of factors that underlie relationships between amyloid and tau deposition\, cognitive decline\, and dementia progression that provide a more informed understanding of individual patient trajectories. These efforts will also be related to familial forms of the disease\, Down Syndrome\, and to non-AD processes (i.e.\, fronto-temporal lobar degeneration and Lewy Body dementia). Further study of “real world” research participants will be discussed that includes people from diverse\, ethnic and/or racial minority\, and disadvantaged groups.\nParticular attention will be given to the assessment of longitudinal amyloid and tau PET data as it relates to methods of analysis and comparison to other domains of data\, including structural and functional brain imaging data\, and clinical and cognitive outcomes. An ongoing topic of importance is the relative value of PET versus other detection strategies (e.g.\, MRI volumetry and biofluid biomarkers).\nAttendees will also continue to have the opportunity the better understand methodology that can be used to optimize participant selection and conduct of AD therapeutic trials. Important topics relate to improved understanding of how in vivo metrics (imaging and non-imaging) and cognition change in response to AD therapeutic treatment (cross-sectionally and longitudinally) and how to better identify those most vulnerable to treatment side-effects\, such as anti-amyloid related imaging abnormalities.\n\nFind out more and register
URL:https://www.dementiaresearcher.nihr.ac.uk/event/human-amyloid-imaging-conference/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2024/09/2025-Human-Amyloid-Imaging-HAI-Conference.png
END:VEVENT
END:VCALENDAR